Invention Grant
US08119616B2 Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
有权
制备含锌结合部分的基于喹唑啉的EGFR抑制剂
- Patent Title: Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
- Patent Title (中): 制备含锌结合部分的基于喹唑啉的EGFR抑制剂
-
Application No.: US12207902Application Date: 2008-09-10
-
Publication No.: US08119616B2Publication Date: 2012-02-21
- Inventor: Xiong Cai , Changgeng Qian , Haixiao Zhai , Rudi Bao
- Applicant: Xiong Cai , Changgeng Qian , Haixiao Zhai , Rudi Bao
- Applicant Address: US MA Lexington
- Assignee: Curis, Inc.
- Current Assignee: Curis, Inc.
- Current Assignee Address: US MA Lexington
- Agency: Elmore Patent Law Group, P.C.
- Agent Edgar W. Harlan; Carolyn S. Elmore
- Main IPC: A01N43/04
- IPC: A01N43/04 ; A61K31/715
Abstract:
The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a β-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
Public/Granted literature
- US20090111772A1 FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY Public/Granted day:2009-04-30
Information query
IPC分类:
